Delivery Order SPE2DB24D1021-SPE2DB25FETJA

Award Date 1/21/25
Potential Completion Date 1/22/25
Potential Value $2.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of PEDVAXHIB vaccine vials (0.5 mL) to the Defense Logistics Agency (DLA), a defense agency. The fixed-price delivery order, valued at $1,413.47, was awarded to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of March 18, 2025 and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a...
This federal contract award is for the delivery of PEDVAXHIB vaccine vials (0.5 mL) to the Defense Logistics Agency (DLA), a defense agency of the U.S. government. The contract, valued at $1,817.10, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order with a firm fixed price type and has an ultimate completion date of November 15, 2024. There is no set-aside designation for this award. Amerisourcebergen...
This federal contract award is for the delivery of PEDVAXHIB VACCINE VIAL 0.5ML to the Defense Logistics Agency (DLA). The $1,752.30 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distributor. The contract has an ultimate completion date of September 25, 2023 and was awarded on September 22, 2023. This delivery order is part of Amerisourcebergen's larger $999,999,999.00 Indefinite Delivery Contract (IDC) with...
This federal contract award is for the delivery of PEDVAXHIB VACCINE VIAL 0.5ML to the Medical Supply Chain of the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., which is a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $2,226.41 and is a Firm Fixed Price Delivery Order that runs through October 30, 2023. The contract was awarded on October 27, 2023...
This federal contract award is for the delivery of the PEDVAXHIB vaccine vial 0.5ML to the Defense Logistics Agency (DLA). The $1,718.45 firm-fixed-price contract was awarded to AmerisourceBergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has an ultimate completion date of July 27, 2023. AmerisourceBergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of the PEDVAXHIB vaccine in 0.5 ml vials. The $7,268.40 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of December 9, 2024. The contract is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This federal contract award to Amerisourcebergen Drug Corporation, a major pharmaceutical distributor, is a $3,140.09 firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) Troop Support Medical. The award is for the delivery of the PEDVAXHIB vaccine in 0.5 milliliter vials to support military healthcare needs. The contract has a period of performance through July 26, 2024 and is not set aside for any specific business type. Amerisourcebergen holds significant Indefinite...
This federal contract award is for the delivery of PEDVAXHIB VACCINE VIAL 0.5ML to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company that serves as a prime contractor for the U.S. government. The contract has a ceiling value of $7,758.87 and is a Firm Fixed Price Delivery Order with a completion date of June 25, 2024. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a larger...
This federal contract award, worth $5,687.70, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of PEDVAXHIB vaccine vials (0.5ML) and has a completion date of February 6, 2025. The contract is a Delivery Order under a Firm Fixed Price arrangement, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,482.08 firm fixed-price delivery order is for the supply of the PEDVAXHIB vaccine, a 0.5 ML vial. The contract has a completion date of November 21, 2024 and was awarded on November 20, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division,...
  • SPE2DB24D1021
    Indefinite Delivery Contract
  • SPE2DB24D1021-SPE2DB25FETJA
    Delivery Order

This federal contract award is for the delivery of PEDVAXHIB vaccine vials (0.5 mL) to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The fixed-price delivery order, valued at $2,905.81, has a completion date of January 22, 2025.

Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, covering similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies for military personnel, veterans, and other federal beneficiaries.

The contract award does not have a set-aside designation, indicating open competition.

Generated 5/21/25, 10:32 AM